On June 5th, Gelonghui reported that Enwei Medicine (301331.SZ) stated on its investor platform that pediatric medicine is one of the company's main global strategic development directions. The company's main pediatric medicines currently include Huaji Oral Liquid, Shanmai Jianpi Oral Liquid, Children's Amoxicillin and Phenylpropanolamine Granules, Children's Asthma Granules, and Jien Medicine Pills. In recent years, it has maintained steady development. By 2023, pediatric medicine will account for 12.69% of the company's total revenue.
恩威医药(301331.SZ)：目前公司主要儿科用药有化积口服液等产品
Currently, Enwei Medicine (301331.SZ)'s main pediatric medications include Huaji oral liquid and other products.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.